Peripheral blood progenitor cell mobilization practices vary significantly among institutions.
Effective mobilization regimens include growth factor alone, chemotherapy and growth factor …

Stem cells harvested from peripheral blood are the most commonly used graft source in
hematopoietic stem cell transplantation. While G-CSF is the most frequently used agent for …

Many lymphoma and myeloma patients fail to undergo ASCT owing to poor mobilization.
Identification of poor mobilizers (PMs) would provide a tool for early intervention with new …

Hematopoietic stem cells intended for autologous transplantation are usually cryopreserved
in solutions containing 10% dimethylsulfoxide (DMSO, v/v) or 5% DMSO in combination with …

CD34+ peripheral blood hematopoietic stem cells (HSC) are usually collected following
mobilization therapy accomplished by using growth factors (GF) such as rHuG-CSF or …

Processing of complex cell preparations such as blood and peripheral blood progenitor cell
(PBPC) transplants using label-free technologies is challenging. Transplant-contaminating …

Background A spontaneous mobilization of Peripheral Blood-Mononuclear CD34+ Cells (PB-
MNC-CD34+) has recently been reported in human myocardial infarction and found to be …

High-risk neuroblastoma is a childhood malignancy with a poor prognosis. Gradual
improvements in survival have correlated with therapeutic intensity, and the ability to …

Mobilized peripheral blood stem cells (PBSC) have become the main source for autologous
or allogeneic transplantation following myeloablative therapy in patients with …

The role of the peripheral blood (PB) CD34+ cell count in predicting the CD34+ cell yield in
hematopoietic progenitor cell apheresis collections is well established. However, sometimes …